BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37024056)

  • 1. Local control correlates with overall survival in radiotherapy for early-stage non-small cell lung cancer: A systematic review.
    Sanuki N; Takeda A; Eriguchi T; Tsurugai Y; Tateishi Y; Kibe Y; Akiba T; Fukuzawa T; Horita N
    Radiother Oncol; 2023 Jun; 183():109664. PubMed ID: 37024056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
    Duvergé L; Bondiau PY; Claude L; Supiot S; Vaugier L; Thillays F; Doyen J; Ricordel C; Léna H; Bellec J; Chajon E; de Crevoisier R; Castelli J
    Lung Cancer; 2021 Jul; 157():100-108. PubMed ID: 34016489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang B; Zhu F; Ma X; Tian Y; Cao D; Luo S; Xuan Y; Liu L; Wei Y
    Radiother Oncol; 2014 Aug; 112(2):250-5. PubMed ID: 25236716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
    Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
    BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy].
    Yu L; Li J; Gao M; Wang X; Bai H; Guan Y; Yuan Z
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):274-280. PubMed ID: 37183642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
    Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
    Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
    Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
    Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
    Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.
    Raghavan G; Shaverdian N; Chan S; Chu FI; Lee P
    Clin Lung Cancer; 2018 Sep; 19(5):e759-e766. PubMed ID: 29954680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Yu T; Shin IS; Yoon WS; Rim CH
    Clin Lung Cancer; 2019 Jul; 20(4):e452-e462. PubMed ID: 31029573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Wang X; Bai H; Gao M; Guan Y; Yu L; Li J; Dong Y; Song Y; Tao Z; Meng M; Wu Z; Zhao L; Yuan Z
    Radiother Oncol; 2023 Sep; 186():109804. PubMed ID: 37437605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
    Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
    Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Propensity-Matched Analysis of Outcomes of Patients with Clinical Stage I Non-Small Cell Lung Cancer Treated surgically or with stereotactic radiotherapy: A Meta-Analysis.
    Wen SW; Han L; Lv HL; Xu YZ; Li ZH; Wang MB; Zhu YG; Su P; Tian ZQ; Zhang YF
    J Invest Surg; 2019 Jan; 32(1):27-34. PubMed ID: 28985095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.